Abstract
Objectives To assess the effects of 24 weeks active treatment with baricitinib, a JAK1/2 inhibitor, in adult idiopathic inflammatory myopathy (IIM).
Methods Patients with active dermatomyositis (DM) or polymyositis (PM) were enrolled into a 1:1 randomized treatment delayed-start design clinical trial (NCT04208464). Participants received 24 weeks baricitinib plus 12 weeks follow-up (Immediate-start), or 12 weeks standard of care plus 24 weeks baricitinib (Delayed-start). The primary outcome was clinical response after 24 weeks active treatment, defined as minimal improvement (Total Improvement Score >20 [TIS20]). Secondary outcomes included: TIS40 (moderate), TIS60 (major) response, between-arm comparison, time to achieve response, change in clinical outcome measures. steroid-sparing and cumulative adverse events.
Results 14/15 (93%) randomized participants (mean age 43.2 years [11.6 SD]; 13 DM, 2 PM; 11 female) completed the study (baseline to 36 weeks) and all achieved TIS20 at 24 weeks post-active treatment (95% exact CI 0.68-1.00). 9/15 (60%) achieved TIS40 response and 2/15 (13%) TIS60 response. At 12 weeks post-randomization, 11/15 (73%) patients achieved at least TIS20 (95%CI 0.45-0.92), including all Immediate-start arm patients and four Delayed-start arm patients. At the same time point, evidence of a difference was noted for patient global, extramuscular, CDASI skin activity, pain, fatigue and SF-36 mental/physical health scores. Two hospitalisation serious adverse events were documented, neither related to study drug.
Conclusions Treatment of IIM with baricitinib resulted in improved clinical outcome after 24 weeks. Significant improvement after 12 weeks treatment was also evident. No significant safety concerns were raised. A randomized placebo-controlled trial is needed to confirm the efficacy in patients with IIM.
Clinical trial registration EudraCT Number: 2019-003868-42
ISRCTN Number /Clinical trials.gov Number: NCT04208464
Competing Interest Statement
HC has received grant support from Pfizer; has received consulting fees from argenx, Astra Zeneca, Boehringer Ingelheim, Pfizer, J&J, Xencor; speaking engagements from CabalettaBio, Data and Science Monitoring Board chair for Horizon Therapeutics; AP has received speaker fees from Boehringer Ingelheim. JAL has received grant support from Pfizer. ST has received honorarium from Boehringer Ingelheim, Bamboo medical and Priovant JBL has received advisory board payments from Roche and Abcuro, speakers fees from Roche and Dyne pharmaceuticals, research support from Roche, travel/conference support from Roche and AstraZeneca. IEL has funding support from: Swedish Research Council, 2024-02582, the Swedish Rheumatism Association, R-1013188; Region Stockholm RS2022-0674, King Gustaf V 80th Year Foundation FAI-2024-1092. I.E.L. has received honorarium for lecture from Boehringer Ingelheim, research grant from Astra Zeneca and Janssen Pharmaceutica NV, and has been serving on the advisory board for Astra-Zeneca, argenx, Chugai, Novartis, Pfizer and Janssen Pharmaceutica NV, and has stock shares in Roche and Novartis.
Clinical Trial
NCT04208464
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Research Ethics Committee approval was obtained from UK Health Research Authority (HRA) prior to commencement of the trial (reference 20/NW/0138). Local site permissions were obtained as required in accordance with HRA guidance and institutional requirements. All participants provided informed consent. T
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
Funder Information Declared
